Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NCI-MATCH closed this year, as three new precision medicine trials — ComboMATCH, MyeloMATCH and iMATCH — are getting underway.
Cabometyx improved progression-free survival versus placebo in people with neuroendocrine tumors inside or outside the pancreas.
Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.
The targeted therapy delayed disease progression or death by approximately nine months.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
Opdivo plus Cabometyx reduced the risk of death by 40%.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
Cabometyx is the third liver cancer drug approved in the past six months.
Median progression-free survival 5.2 months in cabozantinib arm versus 1.9 months in placebo arms.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.